Conditions: Chronic Myelogenous Leukemia
Keywords: Chronic myelogenous leukemia (CML): Accelerated phase
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 197
Healthy volunteers: no

Brief summary:
The purpose of this clinical research study is to learn if BMS-354825 will have activity, defined by hematologic response, in subjects who have accelerated phase chronic myeloid leukemia (CML) who are resistant to or intolerant to imatinib mesylate. The safety of this treatment will also be studied.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Dasatinib
Intervention descriptions: intervention 1: Tablets, Oral, 70 mg, twice daily, until disease progression or intolerable toxicity, switch to the roll-over study or study closure

Protocol document: